off-target toxicities,” said Professor Marcia S. Brose, director of the Center for Rare Cancers and Personalized Therapy at the Abramson Cancer Center and coauthor of the ARROW trial. Pralsetinib is a once-daily oral therapy that selectively targets oncogenic RET alterations, providing a more precise and effective treatment option for patients with these specific types of thyroid cancer. The approval of pralsetinib represents a significant advancement in the treatment of RET-mutant MTC and RET fusion-positive thyroid cancer, offering a targeted treatment option with potentially fewer side effects compared to traditional therapies.
Source link
Gavreto Approved for Treatment of RET-Altered Thyroid Cancers
